CoChat

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

Open access

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

Potentiating anti-tumor immunity by inducing tumor inflammation and T cell-mediated responses are a promising area of cancer therapy. Immunomodulatory agents that promote these effects function via a wide variety of mechanisms, including upregulation of antigen presentation pathways. Here, we show that major histocompatibility class-I (MHC-I) genes are methylated in human breast cancers, suppressing their expression. Treatment of breast cancer cell lines with a next-generation hypomethylating agent, guadecitabine, upregulates MHC-I expression in response to interferon-γ. In murine tumor models of breast cancer, guadecitabine upregulates MHC-I in tumor cells promoting recruitment of CD8+ T cells to the microenvironment. Finally, we show that MHC-I genes are upregulated in breast cancer patients treated with hypomethylating agents. Thus, the immunomodulatory effects of hypomethylating agents likely involve upregulation of class-I antigen presentation to potentiate CD8+ T cell responses. These strategies may be useful to potentiate anti-tumor immunity and responses to checkpoint inhibition in immune-refractory breast cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-02630-w

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 DMTi treatment augments MHC-I and MHC-II expression of human breast cancer samples. a Correlation matrix of methylation status and mRNA expression of MHC-I (HLA-A/B/C), MHC-II (HLA-DRA), and PD-L1 (CD274) from TCGA breast cancer patient data. Pearson’s correlation coefficients are shown in box. b Geometric mean fluorescence intensity (GMFI) ratio of MHC-I and MHC-II in multiple subtypes of human breast cancer cell lines (ER+/MCF7; HER2+/BT474; Claudin-low/BT549; TNBC/HCC1395) under guadecitabine (DMTi) treatment + IFNγ stimulation. GMFI ratio of diluent group was used as the baseline. *p < 0.05; **p < 0.01; ****p < 0.0001 (one-way ANOVA with Tukey’s multiple comparisons correction to compare individual groups). All data are means ± SEM. Each dot represents one independent experimental result. c Viability assay of multiple subtypes of human breast cancer cell lines (ER+/MCF7; HER2+/BT474; Claudin-low/BT549; TNBC/HCC1395) under DMTi treatment. All data are means ± SD
Fig. 1 DMTi treatment augments MHC-I and MHC-II expression of human breast cancer samples. a Correlation matrix of methylation status and mRNA expression of MHC-I (HLA-A/B/C), MHC-II (HLA-DRA), and PD-L1 (CD274) from TCGA breast cancer patient data. Pearson’s correlation coefficients are shown in box. b Geometric mean fluorescence intensity (GMFI) ratio of MHC-I and MHC-II in multiple subtypes of human breast cancer cell lines (ER+/MCF7; HER2+/BT474; Claudin-low/BT549; TNBC/HCC1395) under guadecitabine (DMTi) treatment + IFNγ stimulation. GMFI ratio of diluent group was used as the baseline. *p < 0.05; **p < 0.01; ****p < 0.0001 (one-way ANOVA with Tukey’s multiple comparisons correction to compare individual groups). All data are means ± SEM. Each dot represents one independent experimental result. c Viability assay of multiple subtypes of human breast cancer cell lines (ER+/MCF7; HER2+/BT474; Claudin-low/BT549; TNBC/HCC1395) under DMTi treatment. All data are means ± SDCC BY · PubMed Central
Fig. 2 DMTi treatment augments MHC-I and MHC-II, but not PD-L1 expression on the cell surface upon IFNγ stimulation. a Viability assay of MMTV-Neu cells under guadecitabine (DMTi) treatment. All data are means ± SD. Dotted lines represent doses used in subsequent studies (0.5 and 0.05ug/mL). b Representative anti-5-mC dot blot of DNA isolated from MMTV-Neu cells under different concentrations (µg/ml; blot map in lower panel) of DMTi treatment. c Quantification of (b) based on integrated density of each dot. All data are means ± SD. d Fold change of GMFI of MHC-I, MHC-II and PD-L1 in MMTV-Neu cell line with guadecitabine treatment + IFNγ stimulation. GMFI ratio of diluent group was used as the baseline. *p < 0.05; **p < 0.01 (one-way ANOVA with Tukey’s post-hoc test). All data are mean ± SEM. Each data point represents one independent experimental result. e Methylation-specific PCR for CpG-rich region of the H-2Dq promoter in MMTV-neu cells. Genomic DNA isolated from cells 7 days after treatment with 0.5 µg/mL or 2 µg/mL guadecitabine were bisulfite-treated and analyzed by PCR using paired PCR primers specific for modified (methylated) and unmodified (unmethylated) cytosines. f Quantitative real-time PCR using three primer sets targeting mRNA expression of the H-2Dq allele of MMTV-neu cells after 7 days after treatment with 0.05 µg/mL or 0.5 µg/mL guadecitabine or diluent control and with or without 24 h of stimulation with IFNγ (100 ng/mL)
Fig. 2 DMTi treatment augments MHC-I and MHC-II, but not PD-L1 expression on the cell surface upon IFNγ stimulation. a Viability assay of MMTV-Neu cells under guadecitabine (DMTi) treatment. All data are means ± SD. Dotted lines represent doses used in subsequent studies (0.5 and 0.05ug/mL). b Representative anti-5-mC dot blot of DNA isolated from MMTV-Neu cells under different concentrations (µg/ml; blot map in lower panel) of DMTi treatment. c Quantification of (b) based on integrated density of each dot. All data are means ± SD. d Fold change of GMFI of MHC-I, MHC-II and PD-L1 in MMTV-Neu cell line with guadecitabine treatment + IFNγ stimulation. GMFI ratio of diluent group was used as the baseline. *p < 0.05; **p < 0.01 (one-way ANOVA with Tukey’s post-hoc test). All data are mean ± SEM. Each data point represents one independent experimental result. e Methylation-specific PCR for CpG-rich region of the H-2Dq promoter in MMTV-neu cells. Genomic DNA isolated from cells 7 days after treatment with 0.5 µg/mL or 2 µg/mL guadecitabine were bisulfite-treated and analyzed by PCR using paired PCR primers specific for modified (methylated) and unmodified (unmethylated) cytosines. f Quantitative real-time PCR using three primer sets targeting mRNA expression of the H-2Dq allele of MMTV-neu cells after 7 days after treatment with 0.05 µg/mL or 0.5 µg/mL guadecitabine or diluent control and with or without 24 h of stimulation with IFNγ (100 ng/mL)CC BY · PubMed Central
Fig. 3 DMTi treatment increased tumor-infiltrating CD8+ T cells and promotes tumor regression in vivo. a Representative anti-5-mC dot blot of DNA isolated from MMTV-Neu tumors under in vivo administration of different concentrations of guadecitabine (DMTi) and corresponding quantification based on integrated density. * p < 0.05 (one-way ANOVA with Dunnett’s post-hoc test). All data are means ± SEM. Each dot represents one experimental result. b Evaluation of CD8+ infiltration in MMTV-Neu tumors by IHC under in vivo administration of diluent vs DMTi. The result was illustrated as percentage of CD8+ over the whole tumor section (left) or the ratio of CD8+ infiltration between intra-tumor and stroma compartments (right). P values were calculated using an unpaired t-test. All data are represented as mean ± SEM. Each dot represents data collected from one experimental mouse. c Representative CD8+ IHC of MMTV-Neu tumors after in vivo administration of diluent vs DMTi. The black line outlines margins between tumor and stroma compartments. Scale bar represents 100 µm. d GMFI of MHC-I in the EpCAM+ gated population of dissociated MMTV-Neu tumor samples following in vivo administration of guadecitabine or diluent control. P-values were calculated using an unpaired t-test. All data are means + SEM. Each dot represents one dissociated tumor sample from one experiment mouse. e Quantification of [89Zr]CD8 radioactivity by ImmunoPET in mice orthotopically injected with MMTV-Neu cells under in vivo administration of Diluent vs DMTi. The p-value was calculated using unpaired t test. All data are means + SEM. Each dot represents one experimental mouse. f Representative ImmunoPET images of mice orthotopically injected with MMTV-Neu cells and treated with guadecitabine or diluent control (7 days post-therapy initiation). g Waterfall plot of MMTV-Neu tumor volume following treatment with guadecitabine or diluent control. The result was illustrated as the percentage of tumor volume change from baseline. h Tumor growth curve of MMTV-Neu tumors following in vivo administration of diluent vs DMTi on days 1–3
Fig. 3 DMTi treatment increased tumor-infiltrating CD8+ T cells and promotes tumor regression in vivo. a Representative anti-5-mC dot blot of DNA isolated from MMTV-Neu tumors under in vivo administration of different concentrations of guadecitabine (DMTi) and corresponding quantification based on integrated density. * p < 0.05 (one-way ANOVA with Dunnett’s post-hoc test). All data are means ± SEM. Each dot represents one experimental result. b Evaluation of CD8+ infiltration in MMTV-Neu tumors by IHC under in vivo administration of diluent vs DMTi. The result was illustrated as percentage of CD8+ over the whole tumor section (left) or the ratio of CD8+ infiltration between intra-tumor and stroma compartments (right). P values were calculated using an unpaired t-test. All data are represented as mean ± SEM. Each dot represents data collected from one experimental mouse. c Representative CD8+ IHC of MMTV-Neu tumors after in vivo administration of diluent vs DMTi. The black line outlines margins between tumor and stroma compartments. Scale bar represents 100 µm. d GMFI of MHC-I in the EpCAM+ gated population of dissociated MMTV-Neu tumor samples following in vivo administration of guadecitabine or diluent control. P-values were calculated using an unpaired t-test. All data are means + SEM. Each dot represents one dissociated tumor sample from one experiment mouse. e Quantification of [89Zr]CD8 radioactivity by ImmunoPET in mice orthotopically injected with MMTV-Neu cells under in vivo administration of Diluent vs DMTi. The p-value was calculated using unpaired t test. All data are means + SEM. Each dot represents one experimental mouse. f Representative ImmunoPET images of mice orthotopically injected with MMTV-Neu cells and treated with guadecitabine or diluent control (7 days post-therapy initiation). g Waterfall plot of MMTV-Neu tumor volume following treatment with guadecitabine or diluent control. The result was illustrated as the percentage of tumor volume change from baseline. h Tumor growth curve of MMTV-Neu tumors following in vivo administration of diluent vs DMTi on days 1–3CC BY · PubMed Central
Fig. 4 Guadecitabine enhances IFNγ-mediated MHC-I expression and Cxcr3 ligands. a MMTV-neu tumors were resected 7 days after a 3-day in vivo treatment course with guadecitabine or diluent control. Tumor RNA was extracted and utilized for NanoString gene expression analysis using the PanCancer Immune Pathways codeset (>700 immune-related genes). Genes significantly altered (nominal p-value < 0.05) between the treatment groups are shown with a row-standardized z-scores in heatmap form. Association of altered genes with key pathways are color coded on the right. b MMTV-neu cells were cultured for 7 days with the indicated doses of guadecitabine, followed by 24 h treatment with IFNγ and evaluation by western blot analysis. c MMTV-neu cells were treated as in b but co-treated with or without BMS-345541 (during last 24 h, in tandem with IFNγ) and assessed by flow cytometry for MHC-I. Data represent the mean of four experiment replicates ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns nonsignificant. d qRT-PCR for Cxcr3 ligands in MMTV-neu cells after 7 days of guadecitabine treatment at the indicated doses and 24 h treatment with IFNγ. Data represent the mean of 3 experiment replicates ± SEM. e Relative mRNA expression of Cxcr3 ligands in MMTV-neu cells after 7 days of treatment with guadecitabine (0.5 µg/mL) or diluent control, and 24 h exposure to 10 µM BMS-345541. Data represent the mean of 3 experiment replicates ± SEM
Fig. 4 Guadecitabine enhances IFNγ-mediated MHC-I expression and Cxcr3 ligands. a MMTV-neu tumors were resected 7 days after a 3-day in vivo treatment course with guadecitabine or diluent control. Tumor RNA was extracted and utilized for NanoString gene expression analysis using the PanCancer Immune Pathways codeset (>700 immune-related genes). Genes significantly altered (nominal p-value < 0.05) between the treatment groups are shown with a row-standardized z-scores in heatmap form. Association of altered genes with key pathways are color coded on the right. b MMTV-neu cells were cultured for 7 days with the indicated doses of guadecitabine, followed by 24 h treatment with IFNγ and evaluation by western blot analysis. c MMTV-neu cells were treated as in b but co-treated with or without BMS-345541 (during last 24 h, in tandem with IFNγ) and assessed by flow cytometry for MHC-I. Data represent the mean of four experiment replicates ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns nonsignificant. d qRT-PCR for Cxcr3 ligands in MMTV-neu cells after 7 days of guadecitabine treatment at the indicated doses and 24 h treatment with IFNγ. Data represent the mean of 3 experiment replicates ± SEM. e Relative mRNA expression of Cxcr3 ligands in MMTV-neu cells after 7 days of treatment with guadecitabine (0.5 µg/mL) or diluent control, and 24 h exposure to 10 µM BMS-345541. Data represent the mean of 3 experiment replicates ± SEMCC BY · PubMed Central
Fig. 5 Epigenetic treatment augments MHC-I and MHC-II in breast cancer patient samples, and potentiates response to anti-PD-L1 therapy in mice. a The heatmap illustrates post/pre-treatment mRNA expression ratio of MHC-I, MHC-II, and PD-L1 in 5 pairs of triple negative breast cancer patient samples. Each pair includes “Pre” (before 5’-azacitidine, AZA, and entinostat treatment) and “post” (ratio of 8wks:baseline in patients 1–5 or ratio of 6mos: baseline [patient 5b] after AZA and entinostat treatment). MHC-I nc: non classical MHC-I b Tumor growth curves from MMTV-Neu tumor-bearing FVB/n mice treated with guadecitabine daily for 3 days, followed by twice weekly anti-PD-L1 for 2 weeks (or appropriate controls). Mice were sacrificed when tumor volume measurements first exceeded 2 cm3, or at 4 weeks whichever occurred first. c Final tumor volumes at the humane endpoint by treatment group from (b). Differences in final tumor volume (mean ± SEM) were compared by ANOVA followed by Tukey’s post-hoc test to compare relevant groups. *p < 0.05; ***p < 0.001; ****p < 0.0001 for individual comparisons. d Tumor growth curves from MMTV-PyVmT tumor-bearing FVB/n mice treated with guadecitabine daily for 3 days, followed by twice weekly anti-PD-L1 for 2 weeks (or appropriate controls). Mice were sacrificed when tumor volume measurements first exceeded 2 cm3, or at 4 weeks whichever occurred first. e Final tumor volumes at the humane endpoint by treatment group from (d). Differences in final tumor volume (mean ± SEM) were compared by ANOVA followed by Tukey’s post-hoc test to compare relevant groups. *p < 0.05; **p < 0.01 for individual comparisons
Fig. 5 Epigenetic treatment augments MHC-I and MHC-II in breast cancer patient samples, and potentiates response to anti-PD-L1 therapy in mice. a The heatmap illustrates post/pre-treatment mRNA expression ratio of MHC-I, MHC-II, and PD-L1 in 5 pairs of triple negative breast cancer patient samples. Each pair includes “Pre” (before 5’-azacitidine, AZA, and entinostat treatment) and “post” (ratio of 8wks:baseline in patients 1–5 or ratio of 6mos: baseline [patient 5b] after AZA and entinostat treatment). MHC-I nc: non classical MHC-I b Tumor growth curves from MMTV-Neu tumor-bearing FVB/n mice treated with guadecitabine daily for 3 days, followed by twice weekly anti-PD-L1 for 2 weeks (or appropriate controls). Mice were sacrificed when tumor volume measurements first exceeded 2 cm3, or at 4 weeks whichever occurred first. c Final tumor volumes at the humane endpoint by treatment group from (b). Differences in final tumor volume (mean ± SEM) were compared by ANOVA followed by Tukey’s post-hoc test to compare relevant groups. *p < 0.05; ***p < 0.001; ****p < 0.0001 for individual comparisons. d Tumor growth curves from MMTV-PyVmT tumor-bearing FVB/n mice treated with guadecitabine daily for 3 days, followed by twice weekly anti-PD-L1 for 2 weeks (or appropriate controls). Mice were sacrificed when tumor volume measurements first exceeded 2 cm3, or at 4 weeks whichever occurred first. e Final tumor volumes at the humane endpoint by treatment group from (d). Differences in final tumor volume (mean ± SEM) were compared by ANOVA followed by Tukey’s post-hoc test to compare relevant groups. *p < 0.05; **p < 0.01 for individual comparisonsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 275

Metadata

Authors
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., Sanders, M. E., Manning, H. C., & Balko, J. M.
Affiliations
  • Nankai University (CN)
  • Vanderbilt University Medical Center (US)
  • Pennsylvania State University (US)
  • Johns Hopkins University (US)
Corresponding author
Balko, Justin M.
Venue
Nature Communications
Published
2018-01-16
Volume
9
Issue
1
Pages
248-248
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2784179963
Cited by
275
References
29
Citations by year
2026: 29 · 2025: 35 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 36 · 2020: 40 · 2019: 13 · 2018: 4
FWCI
8.74
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • V Foundation for Cancer Research
  • Vanderbilt University (P30 CA68485, CA68485)
  • Vanderbilt-Ingram Cancer Center (P30 CA 68485, CA098131, CA68485, Support Grant P30 CA68485)
  • China Scholarship Council
  • National Institutes of Health (1s10od016245-01, CA68485, CA098131)
  • National Cancer Institute (P30 CA 68485, CA 098131, CA68485, P50CA098131, R00CA181491, P30CA068485)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
DNA methyltransferase inhibition, MHC class I, breast cancer, guadecitabine, hypomethylating agents, CD8+ T cells, cytotoxic T lymphocytes, antigen presentation, interferon-gamma, tumor immunology, immunomodulation, immune checkpoint blockade
MeSH terms
DNA (Cytosine-5-)-Methyltransferase 1, Animals, Antineoplastic Agents, Azacitidine, Breast Neoplasms, Female, Genes, MHC Class I, Humans, Mammary Neoplasms, Experimental, Promoter Regions, Genetic, T-Lymphocytes, Cytotoxic, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. https://app.cochat.ai/papers/10.1038/s41467-017-02630-w
The paper
Luo, N., Nixon, M. J., Gonzalez-Ericsson, P. I., Sanchez, V., Opalenik, S. R., Li, H., Zahnow, C. A., Nickels, M. L., Liu, F., Tantawy, M. N., Sanders, M. E., Manning, H. C., & Balko, J. M. (2018). DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nature Communications. https://doi.org/10.1038/s41467-017-02630-w

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.